Legal Newsline

Friday, April 3, 2020

Boston Scientific must move forward with buying company - even after exec found to have misled FDA

State Court

By Charmaine Little | Jan 9, 2020


WILMINGTON, Del. (Legal Newsline) – The Court of Chancery of the State of Delaware ruled on Dec. 18 that a company was not entitled to terminate a merger agreement after learning a vice president of the company it agreed to purchase falsified reports.

Channel Medsystems Inc. took legal action against Boston Scientific Corp. and NXT Merger Corp. after Boston Scientific ended its partnership with Channel following news that Channel’s VP of Quality Dinesh Shankar falsified documents that were sent to the Food and Drug Administration for approval of the Cerene device and expense reports. In light of this, Boston Scientific parted ways with Channel in May 2018. 

But Boston Scientific and Channel had an agreement that Boston Scientific would be required to close the merger if Cerene was approved by Sept. 30, 2019. The FDA approved it on March 28, 2019, so Channel sued.

“The court finds that although Shankar’s fraud caused a number of representations to be inaccurate as of the date of the agreement, Boston Scientific failed to prove that the failure of such representations to be true and accurate reasonably would be expected to have material and adverse effect,” wrote Chancellor Andre G. Bouchard. 

Considering this, he ruled that Boston Scientific was not allowed to prematurely end its agreement with Channel even amid Shankar’s misconduct.

The chancellor also noted that Boston Scientific failed to prove that Chanel was aware of any fraudulent activity such as any sign that its internal audit reports were being falsified.

Boston Scientific argued that Channel ignored the warning signs because it wanted to push through and sell the company. 

“This is speculation – not evidence," Bouchard wrote. "What the record shows is that Channel was transparent with the FDA and Boston Scientific upon discovering Shankar’s fraud, and acted with dispatch to address it. This type of responsible conduct is hardly what one would expect from someone intent on turning a blind eye.”

Ultimately, because Boston Scientific failed to prove that Channel acted recklessly in an effort to push through its own interests of selling the company, the chancellor ruled that Boston Scientific breached the agreement and ruled that Channel is owed an order that would require Boston Scientific to complete the sale.

Want to get notified whenever we write about Delaware Court of Chancery ?

Sign-up Next time we write about Delaware Court of Chancery, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

Delaware Court of Chancery